High expression of FLT3 is a risk factor in leukemia

JIE CHENG\textsuperscript{1,2}, LIJUN QU\textsuperscript{1,2}, JIAN WANG\textsuperscript{1,2}, LEMEI CHENG\textsuperscript{1,2} and YI WANG\textsuperscript{1}

\textsuperscript{1}Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, Jiangsu 215025; \textsuperscript{2}Department of Hematology and Oncology, Anhui Provincial Children's Hospital, Hefei, Anhui 230041, P.R. China

Received January 31, 2017; Accepted August 23, 2017

DOI: 10.3892/mmr.2017.8232

Abstract. Several studies have shown that internal tandem duplication (ITD) of FMS-like tyrosine kinase 3 (FLT3) can result in the failure of leukemia treatment and contribute to a poor prognosis. However, the role of the overexpression of FLT3 in leukemia remains to be fully elucidated. By mining public database, the present study first identified that the expression of FLT3 in leukemia was markedly higher, compared with that in other types of tumor and cell lines, indicating that FLT3 is important in leukemia. In leukemia, FLT3 was found to be significantly upregulated in acute myeloid leukemia and acute lymphoblastic leukemia, and a high expression of FLT3 contributed to reduced survival rates. By analyzing Gene Expression Omnibus and The Cancer Genome Atlas data, it was found that genetic alterations and modification of DNA methylation increased the expression of FLT3 in leukemia. FLT3-ITD and FLT3 tyrosine kinase domain point mutations increased the expression of FLT3 in four independent datasets. In addition, the status of FLT3 gene methylation was negatively correlated with the expression of FLT3, and haploinsufficiency of DNA methyltransferase 1 increased the expression of Flt3 in mouse leukemia cells. By analyzing the enrichment of differentially-expressed genes in chemical and genetic perturbation datasets, it was found that genes, which were upregulated in the FLT3 high expression group had myeloid lymphoid leukemia- and nucleophosmin 1-like signatures, indicating that the overexpression of FLT3 may use the same mechanism to promote leukemia. Collectively, the results of the present study showed that the overexpression of FLT3 is a potential risk factor in leukemia.

Introduction

The FMS-like tyrosine kinase 3 (FLT3) gene, encoding a membrane-bound receptor tyrosine kinase, is crucial in normal hematopoiesis (1,2). It has been reported that FLT3 has two mutation types in leukemia, the most common form of FLT3 mutation is an internal tandem duplication (ITD) within the juxtamembrane domain, which occurs in 15-35% of patients with acute myeloid leukemia (AML) (3-13) and 5-10% of patients with myelodysplasia (MDS) (14,15). Another mutation type is the missense point mutation on the tyrosine kinase domain (TKD), which occurs in 5-10% of patients with AML, 2-5% of patients with MDS and 1-3% of patients with acute lymphoblastic leukemia (ALL) (9,16,17). FLT3-ITD can promote ligand-independent dimerization, autophosphorylation and constitutive activation of the receptor, which lead to the aberrant activation of multiple signaling pathways, including phosphatidylinositol 3-kinase/AKT, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and signal transducer and activator of transcription 5 (STAT5) (18-20). FLT3-TKD also promotes constitutive phosphorylation of the receptor and ligand-independent cell growth (16,17,21).

FLT3 mutations are high risk factors in leukemia, and contribute to increased risk of treatment failure and poor prognosis (7,8). Mutations of FLT3-ITD have been reported to confer resistance to multiple tyrosine kinase inhibitors (22). The mutant allelic burden and ITD length are significantly associated with reduced overall survival and disease-free survival rates (23,24). The detection of ITD mutations at diagnosis is now a routine clinical practice to provide guidance for the optimal treatment of patients with AML.

Several previous studies have shown that the expression of FLT3 is activated in acute promyelocytic leukemia (APL) and adult B lymphoblastic leukemia (25,26), and the upregulation of FLT3 is a passive event in Hoxa9/Meis1-induced AML (27) indicating that the overexpression of FLT3 may have a tumor-promotion effect. In addition, the overexpression of FLT3 has been reported to activate the AKT and MAPK pathways, but not the STAT5 pathway (28), which suggests that the overexpression of FLT3 has overlapping downstream pathways with FLT3-ITD.

In the present study, it was found that FLT3 was upregulated in leukemia, and that the high expression of FLT3 indicated a poor prognosis. By analyzing differentially-expressed genes (DEGs), certain leukemic oncogenes were identified, and the high expression of FLT3 was found to have myeloid lymphoid leukemia (MLL)- and nucleophosmin 1-like (NPM1)-like signatures.
Materials and methods

Expression profile analysis. FLT3 expression data were collected from the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/), cBioportal (29,30), Oncomine (http://www.oncomine.org), Cancer Cell Line Encyclopedia (CCLE; https://portals.broadinstitute.org/ccle/home) (31) and the Human Protein Atlas (HPA; http://www.proteinatlas.org) (32). The expression levels of FLT3 in various normal human tissues and cells were analyzed using three independent databases, which included the GEO GDS3834 dataset, and the HPA and Genotype-Tissue Expression (GTEx; https://www.gtexportal.org/home/) databases. The FLT3 expression data were directly downloaded from the GEO and HPA databases; the tissue with the highest expression of FLT3 was normalized to 1.

To compare the expression of FLT3 in different types of cancer, data were directly downloaded from cBioportal, Oncomine and CCLE, and cancer cell lines with the same tissue origin were classified as the same group.

The expression levels of FLT3 in different types of leukemia, including AML, B-cell ALL, B-cell childhood ALL, chronic lymphocytic leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, pro-B ALL, and T-cell ALL, were analyzed using Oncomine. The peripheral blood mononuclear cells were considered a normal control.

The GDS4306 dataset was used to evaluate the effect of a DNA methyltransferase 1 (DNMT1) haploinsufficiency on the expression of FLT3. To compare the correlation between FLT3 methylation and expression, data were downloaded from cBioportal to perform linear regression. The FLT3 mutated samples and wild-type samples were analyzed separately.

Overall survival analysis. The GSE12417 GEO dataset, which contains data on survival rates and survival status, was selected to draw the overall survival curve, and the median expression of FLT3 was used as the cut-off, according to a previous report (33), to classify patients into a high expression group and low expression group. The top 50% of patients were defined as the high expression group and the lowest 50% patients were defined as the low expression group, according to the expression of FLT3 from high to low. The statistical difference between two curves was calculated using a log-rank test.

Analysis of genetic alterations. In order to summarize the genetic alterations of FLT3 in different types of cancer, The Cancer Genome Atlas (TCGA) data were downloaded through cBioportal. A total of 30 types of cancer, including AML, skin cutaneous melanoma, colorectal adenocarcinoma, esophageal carcinoma, lung adenocarcinoma, stomach adenocarcinoma, lung squamous cell cancer, lymphoid neoplasm diffuse large B-cell lymphoma, bladder urothelial carcinoma, uterine corpus endometrial carcinoma, sarcoma, cholangiocarcinoma, prostate adenocarcinoma, breast invasive carcinoma, glioblastoma multiforme, liver hepatocellular carcinoma, ovarian serous cystadenocarcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, uterine carcinosarcoma, brain lower grade glioma, pancreatic adenocarcinoma, pheochromocytoma and paraganglioma, adenocortical carcinoma, thyroid carcinoma, testicular germ cell cancer, kidney renal papillary cell carcinoma, thymoma, kidney chromophobe and mesothelioma, were selected to analyze FLT3 mutations and copy number alterations.

Screening of DEGs. Three GEO datasets of AML (GSE10358, GSE14468 and GSE34860) were selected to analyze the DEGs between the FLT3 high expression group and FLT3 low expression group. Initially, the raw data in the CEL file were downloaded from the GEO database (34), and the robust multiarray average algorithm in the affy R-3.3.1 package was used to perform background correction, normalization and expression calculation (35-37). The Limma package in R (38) was used to identify the DEGs at the probe level between these two groups. P<0.05 and log2 fold change (FC)>0.585 were used as the cut-off criteria. Finally, these probes were annotated into gene names.

Chemical and genetic perturbations enrichment of DEGs. In order to identify the association between the overexpression of FLT3 and other risk factors for leukemia, the enrichment of DEGs in the chemical and genetic perturbations gene set were determined using Gene Set Enrichment Analysis (http://software.broadinstitute.org/gsea) (39,40). Input of the upregulated and downregulated genes was performed on the website separately, and chemical and genetic perturbations was selected to calculate the enrichment. P<0.05 and FDR q-value <0.05 were used as the cut-off criteria.

Statistical analysis. Student's t-test was used to calculate statistically significant differences between quantitative variables. The log-rank test was used to compare the overall survival curve. P<0.05 was considered to indicate a statistically significant difference. GraphPad Prism 5.01 was used for statistical analysis (GraphPad Software, Inc., La Jolla, CA, USA).

Results

FLT3 is upregulated in leukemia and a high expression of FLT3 is a prognostic biomarker. It has been reported that the FLT3-ITD mutation is correlated with prognosis and drug response in leukemia. To investigate the role of the expression of FLT3 in leukemia, the present study firstly evaluated the expression of FLT3 in different types of cancer and normal tissues. In normal tissues, FLT3 was expressed at high levels in bone marrow, lymph nodes, the thymus and spleen in three independent databases (Fig. 1A), which indicated that FLT3 was involved in hematopoiesis. In cancer, the expression of FLT3 was significantly higher in leukemia, compared with other types of tumor (Fig. 1B and C), and FLT3 was specifically upregulated in AML and ALL (Fig. 1D), suggesting that FLT3 contributed to the progression of AML and ALL. In order to analyze the association between the expression of FLT3 and survival rates in AML, the GSE12417 dataset, in which patients with AML exhibited a normal karyotype, was selected for analysis. Kaplan-Meier survival analysis showed that patients with AML with high expression levels of FLT3 (n=121) had reduced survival rates, compared with those with low expression levels of FLT3 (n=121; P<0.05; Fig. 1E). These
Figure 1. Tissue expression profile identifying the overexpression of FLT3 in leukemia. (A) RNA expression of FLT3 in various normal human tissues and cells, analyzed using three independent databases (HPA, GTEx and GDS3834). Red color indicates relative expression of FLT3, black indicates expression data are not available. (B) TCGA and Oncomine databases were used to evaluate expression levels of FLT3 in different types of tumor. (C) Expression of FLT3 in different cancer cell lines was analyzed using CCLE and Oncomine databases. Cell lines of the same tissue origin were classified into the same group. (D) FLT3 was significantly upregulated in several types of leukemia. The X-axis shows the fold change between different types of leukemia and peripheral blood mononuclear cells. The Y-axis shows the log 10 transformed P-value. Different colors of points indicate different types of leukemia. (E) Results of Kaplan-Meier survival analysis showed that patients with AML and a high expression of FLT3 (n=121) had shorter overall survival rates, compared with those with a low expression of FLT3 (n=121). FLT3, FMS-like tyrosine kinase; HPA, Human Protein Atlas; GTEx, Genotype-Tissue Expression; CCLE, Cancer Cell Line Encyclopedia; AC, adrenocortical carcinoma; AML, acute myeloid leukemia; BUC, bladder urothelial carcinoma; BLGG, brain lower grade glioma; BIC, brain invasion, encephaloma, glioblastoma, meningioma, spina bifida or meningocele; GM, glioblastoma multiforme; HNSCC, head and neck squamous cell carcinoma; KC, kidney chromophobe; KRCCC, kidney renal clear cell carcinoma; LSCC, lung squamous cell carcinoma; LNDLBL, lymph node lymphoma diffuse large B-cell lymphoma; OSC, ovarian serous cystadenocarcinoma; SA, stomach adenocarcinoma; TGCC, testicular germ cell cancer; TCG, thyroid carcinoma; UC, uterine corpus endometrial carcinoma; B-ALL, B-cell acute lymphoblastic leukemia; BA, breast adenocarcinoma; DLBL, diffuse large B-cell lymphoma; EA, endometrial adenocarcinoma; FL, follicular lymphoma; GB, glioblastoma; MB, medulloblastoma; OA, ovarian adenocarcinoma; PM, pleural mesothelioma; Pro-ca, prostate carcinoma; RCC, renal cell carcinoma.
collective data indicated that FLT3 was overexpressed in leukemia and was a prognostic biomarker.

**Expression of FLT3 is regulated by genetic and epigenetic alterations.** In order to determine the mechanism increasing the expression of FLT3 in leukemia, the present study evaluated genetic and epigenetic alterations of FLT3 in AML. By mining TCGA data, it was found that FLT3 was significantly mutated in AML, compared with other types of cancer, which was similar to the results obtained on the expression of FLT3. The results revealed ~28% of patients with AML had somatic mutations in FLT3. Therefore, it was hypothesized that FLT3 mutations may increase the expression of FLT3 in AML. To confirm this, the expression of FLT3 was compared between wild-type and mutated groups in four independent databases, (GSE10358, GSE14468, GSE34860 and TCGA). It was found that ITD and TKD mutations significantly increased the expression of FLT3 (Fig. 2B). In addition, methylation data showed an inverse correlation between FLT3 expression and methylation in leukemia. (D) Gene Expression Omnibus dataset (GDS4306) showed that DNMT1 haploinsufficiency (haplo) increased expression of Flt3 in mouse leukemia cells. FLT3, FMS-like tyrosine kinase; AML, acute myeloid leukemia; DLBC, diffuse large B-cell; GBM, glioblastoma multiforme; ccRCC, clear cell renal cell carcinoma; UC, uterine carcinosarcoma; PCPG, pheochromocytoma and paraganglioma; ACC, adenoid cystic carcinoma; pRCC, papillary renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; WT, wild-type; ITD, internal tandem duplication; TKD, tyrosine kinase domain. DNMT1, DNA methyltransferase 1; *P<0.05, **P<0.01 and ***P<0.001; ns, not significant.
from TCGA was used to compare the association between the expression of FLT3 and methylation status. In AML, the expression of FLT3 was negatively correlated with its methylation (Fig. 2C), indicating that the hypomethylation of FLT3 may be a potential mechanism resulting in the upregulation of FLT3. Of note, mining of the GEO dataset (GDS4306) revealed that the haploinsufficiency of DNMT1 significantly increased the expression of Flt3 in mouse leukemia cells (Fig. 2D), suggesting that DNMT1 modified the methylation of FLT3.

Collectively, these data showed that genetic and epigenetic alterations may be potential mechanisms by which the expression of FLT3 is increased in AML.

High expression of FLT3 has MLL- and NPM1-like signatures. In order to identify the DEGs associated with a high expression of FLT3, three independent AML databases (GSE10358, GSE14468 and GSE34860) were examined (Fig. 3A). The expression of seven genes were significantly upregulated in the FLT3 high expression group, comprising ATP8B4, CCNA1, HOXA10, IQCJ, PBX3, SEL1L3 and SLC2A5. CCNA1, HOXA10, PBX3 and SLC2A5 have been reported to function as oncogenes in leukemia (41-44). A total of 11 genes were downregulated, comprising AHSP, ALAS2, EPB42, FCAR, GBP1, HBG1, LEF1, LT, SLC6A8, TUBB2A and ZFP36L1, as shown in Fig. 3B. The deletion of RNA-binding protein ZFP36L1 has been reported to lead to perturbed thymic development and T lymphoblastic leukemia (45). Subsequently, the present study analyzed the enrichment of these DEGs in the chemical and genetic perturbations dataset. Of note, the seven overexpressed genes were enriched in MLL and NPM1 signatures,
indicating that the majority were also upregulated in MLL- or NPM1-mutated AML (Fig. 3C). The 11 downregulated genes were reduced in hematopoietic stem cells (Fig. 3C). Taken together, these results showed that a high expression of FLT3 was associated with MLL- and NPM1-like signatures.

**Discussion**

In the present study, it was found that the expression of FLT3 was high in normal hematopoietic tissues (Fig. 1A) and, in leukemia, FLT3 was specifically upregulated in AML and ALL (Fig. 1D), indicating that a high expression of FLT3 may contribute to the progression of leukemia. It has been reported that the overexpression of FLT3 can induce autophosphorylation (46), and activate the AKT and MAPK pathways in AML (47). ITD mutations clustered in the juxtamembrane domain of FLT3 are the most frequent forms in AML, and FLT3-ITD mutations are associated with a poor prognosis (47-49). In the present study, it was also found that a high expression of FLT3 was a prognostic factor for poor prognosis in AML using the GEO database (Fig. 1E).

FLT3-related pathways were activated in AML by ITD mutations or the overexpression of FLT3. Several interacting proteins are also reported to interact with FLT3 to negatively or positively regulate FLT3 pathways. Spleen tyrosine kinase (SYK) and the mucin 1-C-terminal subunit (MUC1-C) oncoprotein are reported to directly bind to and activate FLT3-related pathways (50,51), whereas suppressor of cytokine signaling 2 (SOCS2) and src-like adaptor protein 2 (SLAP2) interact with FLT3 protein to inhibit its signaling (52,53). In addition, the transcription of FLT3 can be regulated in AML. Certain AML-related transcription factors, including CCAAT/enhancer binding protein α and the proto-oncogene MYB, can bind to the FLT3 promoter to activate the transcription of FLT3 (54). In the present study, another two mechanism were found to increase the expression of FLT3 in AML. ITD and TKD mutations, and the methylation of FLT3 increased its expression in AML (Fig. 2B and C). In addition, DNMT1 was identified as a potential regulator of FLT3 (Fig. 2D).

By analyzing DEGs in the FLT3 high expression group, a total of 18 genes were identified using three independent AML datasets, seven of which were upregulated and 11 of which were downregulated (Fig. 3B). These upregulated genes were enriched in MLL and NPM1 signatures (Fig. 3C), and CCNA1, HOXA10, PBX3 and SLC2A5 were reported to function as oncogenes in leukemia. CCNA1 was overexpressed in ALL, and patients with high levels of CCNA1 exhibit poor event-free survival rates (55). CCNA1 transgenic mice have also been shown to exhibit abnormal myelopoiesis and progressed to overt AML (40). Similarly, the overexpression of HOXA10 can cooperate with active SHP2 to induce AML (41), and HOXA10 was usually fused with the NUP98, collaborating with overexpressed FLT3 receptor tyrosine kinase to induce aggressive AML (56). PBX3 is an important cofactor of HOXA9 in leukemogenesis (57) and the coexpression of PBX3 and MEIS1 (PBX3/MEIS1) can cause AML in vivo (58). SLC2A5 is also overexpressed in AML and can increase the fructose utilization of leukemic cells, with a high expression of SLC2A5 being associated with poor outcomes (44). Among these 11 downregulated genes, ZFP36L1 has a tumor suppressor role in leukemia. ZFP36L1 is an RNA-binding protein and leads to mRNA degradation; deletion of ZFP36L1 in mice can induce T cell ALL (45).

Collectively the findings obtained in the present study showed that FLT3 is overexpressed in leukemia and is prognostic factor for poor prognosis in AML. Patients with a high expression of FLT3 simultaneously express high levels of leukemic oncogenes. Therefore, a high expression of FLT3 is a risk factor in leukemia.

**Acknowledgements**

This study was supported by a grant from the National Natural Science Foundation of China (grant no. 8130044).

**References**

1. Volpe G, Clarke M, Garcia P, Walton DS, Vegiopoulos A, Del Pozzo L, O'Neill LP, Frampont J and Dumon S: Regulation of the Flt3 gene in hematopoietic stem and early progenitor cells. PLoS One 10: e0138257, 2015.
2. Ebihara Y, Wada M, Ueda T, Xu MJ, Manabe A, Tanaka R, Ito M, Mugishima H, Asano S, Nakahata T and Tsuji K: Reconstitution of human hematopoiesis in non-obese diabetic/severe combined immunodeficient mice by clonal cell expansions from single CD34+CD38+ cells expressing Flk2/Flt3. Br J Haematol 119: 525-534, 2002.
3. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Somoda Y, Fujimoto T and Misawa S: Internal tandem duplication of the Flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911-1918, 1996.
4. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H and Naoe T: Internal tandem duplication of the Flt3 gene is a unique modality of constitutive activation of the Flt3 receptor. Leukemia 12: 1333-1337, 1998.
5. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama Y, Takeshita A, Saito K, Hasegawa S, Shimodaira S, et al: Internal tandem duplication of Flt3 associated with leukocytecysis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11: 1447-1452, 1997.
6. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL and Radich JP: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97: 3589-3595, 2001.
7. Meshinchi S, Woods WG, Stirewalt DL, Sweeter DA, Buckley JD, Tjoa TK, Bernstein ID and Radich JP: Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97: 89-94, 2001.
8. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Liiffler H, Sauerland CM, Serve H, Büchner T, et al: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100: 59-66, 2002.
9. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wernike M, Bornhäuser M, Ritter M, Neubauer A, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326-4335, 2002.
10. Abs-Duhier FM, Goede AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberge EA, Winship PR and Reilly JT: FLT3 internal tandem duplication mutations in adult acute myeloid leukemia define a high-risk group. Br J Haematol 111: 190-195, 2000.
11. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy. Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98: 1752-1759, 2001.
27. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Nat Med 2016: 1201-1207, 2006.

19. Overexpression and constitutive activation of FLT3 in acute myeloid leukemia. Blood 2004: 3423-3425, 2002.

21. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

22. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

23. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

24. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

25. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

26. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

27. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

28. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

29. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

30. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

31. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

32. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

33. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

34. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

35. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

36. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

37. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

38. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

39. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

40. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

41. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

42. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

43. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

44. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

45. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

46. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

47. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

48. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.

49. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013: 48-55, 2013.
50. Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, et al: SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell 25: 226-242, 2014.

51. Liu S, Yin L, Stroopinsky D, Rajabi H, Puissant A, Stegmaier K, Avigan D, Kharbanda S, Kufe D and Stone R: MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood 123: 734-742, 2014.

52. Moharram SA, Chougule RA, Su X, Li T, Sun J, Zhao H, Rönnstrand L and Kazi JU: Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling. Oncotarget 7: 57770-57782, 2016.

53. Kazi JU and Rönnstrand L: Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Mol Oncol 7: 693-703, 2013.

54. Volpe G, Walton DS, Del Pozzo W, Garcia P, Dassé E, O’Neill LP, Griffiths M, Frampton J and Dumon S: C/EBPα and MYB regulate FLT3 expression in AML. Leukemia 27: 1487-1496, 2013.

55. Holm C, Ora I, Brunhoff C, Anagnostaki L, Landberg G and Persson JL: Cyclin A1 expression and associations with disease characteristics in childhood acute lymphoblastic leukemia. Leuk Res 30: 254-261, 2006.

56. Palmqvist L, Argiropoulos B, Pineault N, Abramovich C, Sly LM, Krystal G, Wan A and Humphries RK: The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia. Blood 108: 1030-1036, 2006.

57. Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, Jiang X, Hong GM, Kunjamma RB, Ren H, et al: PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood 121: 1422-1431, 2013.

58. Li Z, Chen P, Su R, Hu C, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, et al: PBX3 and MEIS1 cooperate in hematopoietic cells to drive acute myeloid leukemias characterized by a core transcriptome of the MLL-rearranged disease. Cancer Res 76: 619-629, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.